Literature DB >> 16038051

Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.

Kenichi Nomura1, Koichi Tomikashi, Yosuke Matsumoto, Naohisa Yoshida, Takashi Okuda, Chohei Sakakura, Shoji Mitsufuji, Shigeo Horiike, Hisakazu Yamagishi, Takeshi Okanoue, Masafumi Taniwaki.   

Abstract

A 44-year-old man was referred to our hospital with intermittent abdominal pain. Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction. A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall. Some mesenteric lymph nodes were swollen. Pathological examination was defined. We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses. Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2. Four cycles were performed every 6 mo and he remained CR. Rituximab may be effective as adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038051      PMCID: PMC4434679          DOI: 10.3748/wjg.v11.i28.4443

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  6 in total

1.  A new method of enteroscopy--the double-balloon method.

Authors:  Hironori Yamamoto; Kentaro Sugano
Journal:  Can J Gastroenterol       Date:  2003-04       Impact factor: 3.522

2.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

3.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

4.  Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment.

Authors:  Jeeyun Lee; Won Seog Kim; Kihyun Kim; Young Hyeh Ko; Jae Jun Kim; Young Ho Kim; Ho Kyung Chun; Woo Yong Lee; Joon Oh Park; Chul Won Jung; Young-Hyuck Im; Mark H Lee; Won Ki Kang; Keunchil Park
Journal:  Leuk Lymphoma       Date:  2004-02

5.  Primary lymphoma of the small intestine. A clinicopathological study of 119 cases.

Authors:  P Domizio; R A Owen; N A Shepherd; I C Talbot; A J Norton
Journal:  Am J Surg Pathol       Date:  1993-05       Impact factor: 6.394

6.  Malignant intestinal non-Hodgkin's lymphoma from the surgical point of view.

Authors:  S Samel; J Wagner; R Hofheinz; J Sturm; S Post
Journal:  Onkologie       Date:  2002-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.